Myrobalan Therapeutics

Professor Guoping Feng Member of National Academy of Sciences and National Academy of Medicine

Professor Guoping Feng was elected to the National Academy of Sciences for his contributions to neuroscience.

Approach leverages novel mechanisms such as remyelination and anti-neuroinflammation to address a broad spectrum of degenerative CNS diseases.

Grant funding advances preclinical candidate and deepens the scientific understanding of CSF1R inhibition in ALS. Myrobalan plans to initiate clinical testing in 2025.

Myrobalan is developing medicines to address the unmet need and societal burdens posed by neurodegenerative and demyelinating diseases.

Dr. Angela Genge has directed The Neuro’s ALS clinic since 1998 and its ALS Global Center of Excellence in Patient Care since 2014. She led its Clinical Research Unit from 2004 to 2023.

Dr. Rubin studies neurodegenerative diseases and seeks therapeutic candidates. At Harvard, his work focuses on therapies for Parkinson’s disease, ALS, and spinal muscular atrophy.

Myrobalan Therapeutics is a pre-clinical biotech company developing medicines for neurodegenerative and demyelinating disorders. It targets specialized CNS cells, including microglia and oligodendrocytes.

The company discusses its CNS-focused oral small molecule programs with media, potential investors, development and commercialization partners, and licensors.

The company focuses its strategy on demyelination and neuroinflammation, which it identifies as drivers of multiple sclerosis, Alzheimer's disease, ALS, Parkinson's disease, and other demyelinating and degenerative disorders.

Myrobalan Therapeutics Inc. states that it is committed to protecting privacy.